Novavax stock lost almost a third of its value over the past month driven by the company's announcement that it would delay seeking Emergency Use Authorization of its Covid-19 shot in the U.S., U.K., and Europe to the end of September, falling behind its initial plan of filing by June...
Novavax stock lost almost a third of its value over the past month driven by the company's announcement that it would delay seeking Emergency Use Authorization of its Covid-19 shot in the U.S., U.K., and Europe to the end of September, falling behind its initial plan of filing by June...
Share this Article
Recommended